There were 589 press releases posted in the last 24 hours and 149,487 in the last 365 days.

Human Immunodeficiency Virus (HIV) - Current and Future Players

Human Immunodeficiency Virus (HIV) -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021

PUNE , MAHARASHTRA, INDIA, September 19, 2016 /EINPresswire.com/ -- Human Immunodeficiency Virus (HIV) Industry

Description

Wiseguyreports.Com Adds “Human Immunodeficiency Virus (HIV) -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database

GlobalData has released its pharma report, “Human Immunodeficiency Virus (HIV) - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Human Immunodeficiency Virus (HIV) Market. The report identifies and analyses the key companies shaping and driving the global Human Immunodeficiency Virus (HIV) market. The report provides insight into the competitive Human Immunodeficiency Virus (HIV) landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Report Detail’s@ https://www.wiseguyreports.com/reports/643854-human-immunodeficiency-virus-hiv-current-and-future-players

Scope

- Investigation of current and future market competition for Human Immunodeficiency Virus (HIV)
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Human Immunodeficiency Virus (HIV) sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Human Immunodeficiency Virus (HIV) market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Human Immunodeficiency Virus (HIV) market landscape? Identify, understand and capitalize

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/643854-human-immunodeficiency-virus-hiv-current-and-future-players



Table of Contents

1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 7
2.3 Upcoming Related Reports 7
3 Market Outlook 8
3.1 Global Markets 8
3.1.1 Forecast 8
3.1.2 Drivers and Barriers - Global Issues 14
4 Current and Future Players 17
4.1 Overview 17
4.2 Trends in Corporate Strategy 19
4.3 Company Profiles 21
4.3.1 Gilead Sciences 21
4.3.2 ViiV Healthcare 26
4.3.3 AbbVie 31
4.3.4 Merck & Co. 34
4.3.5 Janssen 38
4.3.6 Bristol-Myers Squibb 42
4.3.7 Japan Tobacco 47
4.3.8 Avexa 50
4.3.9 TaiMed Biologics 53
4.3.10 Tobira Therapeutics 55
5 Appendix 59
5.1 Bibliography 59
5.2 Abbreviations 93
5.3 Methodology 100
5.4 Forecasting Methodology 100
5.4.1 Total Prevalent Cases of HIV 100
5.4.2 20-Year Diagnosed Prevalent Cases of HIV 100
5.4.3 HIV Cases Treated with ART 101
5.4.4 Drugs Included in Each Therapeutic Class 102
5.4.5 Launch and Patent Expiry Dates 103
5.4.6 General Pricing Assumptions 104
5.4.7 Individual Drug Assumptions 106
5.4.8 Generic Erosion 124
5.4.9 Pricing of Pipeline Agents 124
5.5 Primary Research - KOLs Interviewed for This Report 126
5.6 Primary Research - Prescriber Survey 128
5.7 About the Authors 129
5.7.1 Analyst 129
5.7.2 Epidemiologists 129
5.7.3 Therapy Area Director 129
5.7.4 Global Director of Therapy Analysis and Epidemiology 130
5.7.5 Global Head of Healthcare 130
5.8 About GlobalData 131
5.9 Disclaimer 131

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643854

Continued...

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here